LURAP1L as A Potential Drug Target for Depression (G286343)

Target Name: LURAP1L

NCBI ID: G286343

LURAP1L

LURAP1L as A Potential Drug Target for Depression

LURAP1L (Ba3L8.2) is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a member of the T-cell antigen receptor (TCR) family and is involved in the immune response.

The discovery and characterization of LURAP1L was made by researchers at the National Institute of Mental Health (NIMH) in the United States. The study, which was published in the journal Nature Medicine in 2005, identified LURAP1L as a potential drug target for the treatment of depression.

Since then, numerous studies have further characterized the role of LURAP1L in depression and related mood disorders. These studies have shown that LURAP1L is involved in the regulation of cellular processes that are important for the development and progression of depression.

One of the key functions of LURAP1L is its role in the regulation of mitochondrial function. Mitochondria are organelles that are responsible for generating the energy that cells need to function, and they are thought to play a key role in the development of depression.

Research has shown that LURAP1L is involved in the regulation of mitochondrial function by promoting the import of a protein called Cochaperone-2 (CAPN10). This protein is known to play a role in the regulation of mitochondrial function and is thought to be involved in the development of depression.

Another function of LURAP1L is its role in the regulation of cellular signaling pathways. Research has shown that LURAP1L is involved in the regulation of several signaling pathways that are important for the development and progression of depression.

For example, LURAP1L is involved in the regulation of the JAK/STAT signaling pathway, which is involved in the production of pro-inflammatory cytokines that are thought to contribute to the development of depression.

In addition to its role in the regulation of mitochondrial function and cellular signaling pathways, LURAP1L is also involved in the regulation of cellular adhesion. Research has shown that LURAP1L is involved in the regulation of tight junction formation, which is important for the regulation of the movement of cells into and out of tissues.

The identification and characterization of LURAP1L as a potential drug target for depression has led to a number of research studies aimed at understanding its role in this disease. These studies have provided valuable insights into the molecular mechanisms underlying the regulation of LURAP1L in the development and progression of depression.

In addition to its potential as a drug target, LURAP1L is also an attractive biomarker for the diagnosis and assessment of depression. Several studies have shown that LURAP1L is significantly reduced in the blood of individuals with major depressive disorder (MDD), and that these individuals have reduced levels of other proteins that are involved in the regulation of cellular processes, including mitochondrial function and cellular signaling pathways.

Overall, LURAP1L is a protein that is involved in the regulation of various cellular processes that are important for the development and progression of depression. The identification and characterization of LURAP1L as a potential drug target for depression has led to a number of research studies aimed at understanding its role in this disease, and has identified new avenues for the development of new treatments for depression.

Protein Name: Leucine Rich Adaptor Protein 1 Like

The "LURAP1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LURAP1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets